Amedeo Smart

Free Medical Literature Service

 

Amedeo

Influenza
  Free Subscription

Articles published in
Antiviral Res
    May 2026
  1. CHIBA S, Kiso M, Yamayoshi S, Uraki R, et al
    Niclosamide inhibits the replication of highly pathogenic avian influenza A (H5Nx) viruses and antiviral-resistant mutants.
    Antiviral Res. 2026;251:106421.
    >> Share

    March 2026
  2. RUDRAMURTHY GR, Gudla CS, Harisha R, Selvam V, et al
    FNDR-11124, a broad-spectrum small molecule inhibitor of viral RNA polymerase, restricts replication of SARS-CoV-2 and Influenza virus in vitro and in vivo.
    Antiviral Res. 2026 Mar 2:106382. doi: 10.1016/j.antiviral.2026.106382.
    >> Share

  3. WRONSKI S, Obernolte H, Schaudien D, Braun A, et al
    Prophylactic intranasal administration of bacterial lysate OM-85 mitigates human rhinovirus (RV-A1b) lung infection and inflammation in mice.
    Antiviral Res. 2026;247:106362.
    >> Share

    February 2026
  4. ZHANG T, Wang ZL, Li XY, Luo RH, et al
    Onvansertib and vilazodone inhibit SARS-CoV-2 replication via suppression of METTL3 RNA-m(6)A enzymatic activity.
    Antiviral Res. 2026 Feb 19:106376. doi: 10.1016/j.antiviral.2026.106376.
    >> Share

  5. TOSELLI F, Jacobs S, Scheers E, Jacobs T, et al
    Optimal preclinical models for human dose projection of SARS-CoV-2 small molecule direct-acting antivirals.
    Antiviral Res. 2026 Feb 9:106363. doi: 10.1016/j.antiviral.2026.106363.
    >> Share

    January 2026
  6. YURGELONIS I, Rai DK, Li Z, Washington B, et al
    Analysis of Ibuzatrelvir's Activity Against SARS-CoV-2 Circulating Variants and In Vitro Resistance Mutations.
    Antiviral Res. 2026 Jan 30:106352. doi: 10.1016/j.antiviral.2026.106352.
    >> Share

  7. HEDSKOG C, Rodriguez L, Hu Y, Li J, et al
    SARS-CoV-2 Resistance Analyses From the Phase 3 BIRCH Study of Obeldesivir in High-Risk Nonhospitalized Participants With COVID-19.
    Antiviral Res. 2026 Jan 19:106351. doi: 10.1016/j.antiviral.2026.106351.
    >> Share

  8. LEEKHA A, Reichel K, Hurst B, Varadarajan N, et al
    Therapeutic intranasal delivery of NanoSTING provides broad protection against seasonal and highly pathogenic influenza strains.
    Antiviral Res. 2026 Jan 14:106342. doi: 10.1016/j.antiviral.2026.106342.
    >> Share

    December 2025
  9. RODRIGUEZ L, Hu Y, Li J, Han D, et al
    SARS-CoV-2 Resistance Analyses From the Phase 3 OAKTREE Study of Obeldesivir in Low-Risk Nonhospitalized Participants With COVID-19.
    Antiviral Res. 2025 Dec 29:106339. doi: 10.1016/j.antiviral.2025.106339.
    >> Share

  10. XIONG R, Wu Y, Wang Y, Qu Z, et al
    Rapid generation of a murine RSV infectious model by transducing a conditional knock-in mouse harboring human IGF1 receptor with adenoviral vector.
    Antiviral Res. 2025;244:106304.
    >> Share

  11. SUTTO-ORTIZ P, Selisko B, Ferron F, Sommadossi JP, et al
    Mapping the impact of 1'-, 2'- and 4'-nucleotide modifications on the Respiratory Syncytial Virus RNA-dependent RNA polymerase.
    Antiviral Res. 2025;244:106298.
    >> Share

    October 2025
  12. BESSONNE M, Morel J, Nevers Q, Groutsch J, et al
    Inhibition of influenza virus replication by artificial proteins (alphaReps) targeting its RNA-polymerase.
    Antiviral Res. 2025 Oct 21:106300. doi: 10.1016/j.antiviral.2025.106300.
    >> Share

  13. PATEL MC, Nguyen HT, Mishin VP, Pascua PNQ, et al
    Antiviral susceptibility monitoring: testing algorithm, methods, and findings for influenza season, 2023-2024.
    Antiviral Res. 2025 Oct 11:106299. doi: 10.1016/j.antiviral.2025.106299.
    >> Share

  14. SCHRELL L, Scheibner D, Dickmanns A, Stegmann KM, et al
    Inhibitors of pyrimidine synthesis synergize with N4-hydroxycytidine to diminish influenza virus replication.
    Antiviral Res. 2025 Oct 3:106286. doi: 10.1016/j.antiviral.2025.106286.
    >> Share

    September 2025
  15. ZHANG W, Prevost J, Sloan A, Tamming L, et al
    Intranasal vaccine induces broad and long-lasting immunity against the hemagglutinin stem of group 2 influenza A viruses.
    Antiviral Res. 2025;243:106284.
    >> Share

  16. ZHU C, Wang Z, Pan Z, Mai X, et al
    DMBT1 promotes SARS-CoV-2 infection and its SRCR-derived peptide inhibits SARS-CoV-2 infection.
    Antiviral Res. 2025 Sep 3:106269. doi: 10.1016/j.antiviral.2025.106269.
    >> Share

  17. TASHIMA R, Kuroda T, Nobori H, Miyagawa S, et al
    Ensitrelvir suppresses prolonged olfactory abnormalities derived from SARS-CoV-2 infection in hamsters.
    Antiviral Res. 2025 Sep 2:106270. doi: 10.1016/j.antiviral.2025.106270.
    >> Share

    August 2025
  18. ICHIKAWA T, Tamura T, Nao N, Suzuki H, et al
    Characterization of remdesivir resistance mutations in COVID-19 patients with various immunosuppressive diseases.
    Antiviral Res. 2025;242:106264.
    >> Share

  19. BI W, Zhu T, Xu Y, Chen Y, et al
    An engineered chimeric ACE2-HR2 peptide exhibits potent and broad-spectrum activity against SARS-CoV-2 variants.
    Antiviral Res. 2025;242:106265.
    >> Share

  20. TERATAKE Y, Okamura T, Ishizaka Y
    SMAD5 phosphorylation by ALK1 is modulated by the interaction of the spike protein of SARS-CoV-2 and angiotensin-converting enzyme 2.
    Antiviral Res. 2025;242:106261.
    >> Share

  21. GUAN S, Wang Q, Nie J, Yao X, et al
    Optimization of the monoclonal antibody 3E1 through W32I mutation enhances antiviral efficacy against influenza virus subtypes H1N1 and H3N2.
    Antiviral Res. 2025;242:106260.
    >> Share

  22. LUO YS, Shen H, Ling P, Gao H, et al
    Tirofiban protects mice against severe RSV pneumonia by potentially inhibiting platelet activation via the GPIbalpha-vWF pathway.
    Antiviral Res. 2025;240:106207.
    >> Share

  23. YAO G, Shi X, Jiang H, Duan A, et al
    Design, synthesis, and biological evaluation of novel 6-aminoalkyl- and 7-heteroaryl substituted 7-deazapurine nucleoside analogs against SARS-CoV-2 Replication.
    Antiviral Res. 2025 Aug 1:106246. doi: 10.1016/j.antiviral.2025.106246.
    >> Share

    July 2025
  24. AL KRAD D, Stegmann KM, Dickmanns A, Kumar P, et al
    The protease inhibitor Nirmatrelvir synergizes with inhibitors of GRP78 to suppress SARS-CoV-2 replication.
    Antiviral Res. 2025 Jul 29:106247. doi: 10.1016/j.antiviral.2025.106247.
    >> Share

  25. PATEL D, De R, Azadi N, Lee S, et al
    Discovery of broad-spectrum antivirals targeting viral proteases using in silico structural modeling and cellular analysis.
    Antiviral Res. 2025;241:106245.
    >> Share

  26. LEBEDIN M, Petrovsky N, Tabynov K, Tabynov K, et al
    SARS-CoV-2 neutralization and protection of hamsters via nasal administration of a humanized neutralizing antibody.
    Antiviral Res. 2025;241:106235.
    >> Share

    June 2025
  27. HUSSAIN S, Meijer A, Govorkova EA, Dapat C, et al
    Global update on the susceptibilities of influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2020-2023.
    Antiviral Res. 2025 Jun 24:106217. doi: 10.1016/j.antiviral.2025.106217.
    >> Share

  28. MARTINEZ-GZEGOZEWSKA Y, Rasmussen L, Nebane NM, McKellip S, et al
    High-throughput screening for identification of Influenza A inhibitors using a cell-based immunofluorescence assay.
    Antiviral Res. 2025 Jun 6:106209. doi: 10.1016/j.antiviral.2025.106209.
    >> Share

  29. MALUNE P, Esposito F, Tramontano E
    Unveiling SARS-CoV-2's heart: role, structure and inhibition of SARS-CoV-2 RNA-dependent RNA polymerase.
    Antiviral Res. 2025 Jun 3:106208. doi: 10.1016/j.antiviral.2025.106208.
    >> Share

    May 2025
  30. FAGE C, Loison S, Zwygart AC, Poli R, et al
    Influenza A(H1N1)pdm09 Virus Resistance to Baloxavir, Oseltamivir and Sialic Acid Mimetics in Single and Dual therapies: Insights from Human Airway Epithelia and Murine Models.
    Antiviral Res. 2025 May 3:106174. doi: 10.1016/j.antiviral.2025.106174.
    >> Share

  31. TAKASHITA E, Yasui Y, Ikegaya A, Saka K, et al
    Impact of the Polymerase Acidic Protein E199K Substitution in Influenza A Viruses on Baloxavir Susceptibility.
    Antiviral Res. 2025 May 3:106173. doi: 10.1016/j.antiviral.2025.106173.
    >> Share

  32. BONNEUX B, Ceconi M, Stobbelaar K, Herschke F, et al
    Insights in the RSV L polymerase function and structure.
    Antiviral Res. 2025;237:106148.
    >> Share

    March 2025
  33. ZHU Y, Gao Z, Feng X, Hu Y, et al
    Comprehensive preclinical characterization of IPB29, a pan-coronavirus fusion inhibitor under clinical trials.
    Antiviral Res. 2025;237:106154.
    >> Share

  34. KUO YS, Chiang PC, Kuo CY, Huang CG, et al
    Inhibition of influenza A virus proliferation in mice via universal RNA interference.
    Antiviral Res. 2025 Mar 25:106149. doi: 10.1016/j.antiviral.2025.106149.
    >> Share

  35. PADEY B, Droillard C, Duliere V, Fouret J, et al
    Host-targeted repurposed diltiazem enhances the antiviral activity of direct acting antivirals against Influenza A virus and SARS-CoV-2.
    Antiviral Res. 2025 Mar 4:106138. doi: 10.1016/j.antiviral.2025.106138.
    >> Share

    February 2025
  36. BRUN J, Arman BY, Hill ML, Kiappes JL, et al
    Assessment of repurposed compounds against coronaviruses highlights the antiviral broad-spectrum activity of host-targeting iminosugars and confirms the activity of potent directly acting antivirals.
    Antiviral Res. 2025 Feb 23:106123. doi: 10.1016/j.antiviral.2025.106123.
    >> Share

  37. ZIAN D, Iaconis D, Nenci S, Crusco A, et al
    The Efficiency of High-Throughput Screening (HTS) and in-silico data analysis during medical emergencies: identification of effective antiviral 3CLpro inhibitors.
    Antiviral Res. 2025 Feb 18:106119. doi: 10.1016/j.antiviral.2025.106119.
    >> Share

  38. INOUE A, Ichikawa T, Wada D, Maruyama S, et al
    M49L and other drug resistance mutations emerging in individuals after administration of ensitrelvir in Japanese clinical settings.
    Antiviral Res. 2025;236:106118.
    >> Share

  39. TIETJEN I, Kwan DC, Petrich A, Zell R, et al
    Antiviral Mechanisms and Preclinical Evaluation of Amantadine Analogs that Continue to Inhibit Influenza A Viruses with M2(S31N)-Based Drug Resistance.
    Antiviral Res. 2025 Feb 11:106104. doi: 10.1016/j.antiviral.2025.106104.
    >> Share

  40. SCHREIBER A, Ludwig S
    Host-targeted antivirals against SARS-CoV-2 in clinical development - Prospect or disappointment?
    Antiviral Res. 2025;235:106101.
    >> Share

    January 2025
  41. UEHARA T, Yotsuyanagi H, Ohmagari N, Doi Y, et al
    Ensitrelvir treatment-emergent amino acid substitutions in SARS-CoV-2 3CL(pro) detected in the SCORPIO-SR phase 3 trial.
    Antiviral Res. 2025 Jan 30:106097. doi: 10.1016/j.antiviral.2025.106097.
    >> Share

  42. WU Q, Wu H, Hu Y, Zheng X, et al
    Immune evasion of Omicron variants JN.1, KP.2, and KP.3 to the polyclonal and monoclonal antibodies from COVID-19 convalescents and vaccine recipients.
    Antiviral Res. 2025 Jan 24:106092. doi: 10.1016/j.antiviral.2025.106092.
    >> Share

  43. XU M, Zhang Z, Sun Y, Mai H, et al
    IgA class switching enhances neutralizing potency against SARS-CoV-2 by increased antibody hinge flexibility.
    Antiviral Res. 2025 Jan 17:106082. doi: 10.1016/j.antiviral.2025.106082.
    >> Share

  44. MAIA AR, Gonzalez L, Bounab B, Grassi L, et al
    Intranasal exposure to commensal bacterium Rothia mucilaginosa protects against influenza A virus infection.
    Antiviral Res. 2025 Jan 2:106076. doi: 10.1016/j.antiviral.2025.106076.
    >> Share

    December 2024
  45. GAO M, Zhang Z, Yao G, Zhang L, et al
    Design, synthesis, and biological evaluation of novel 2'-deoxy-2'-spirooxetane-7-deazapurine nucleoside analogs as anti-SARS-CoV-2 agents.
    Antiviral Res. 2024 Dec 30:106060. doi: 10.1016/j.antiviral.2024.106060.
    >> Share

  46. MERCURI FA, Anderson GP, Miller BE, Demaison C, et al
    Discovery and development of INNA-051, a TLR2/6 agonist for the prevention of complications resulting from viral respiratory infections.
    Antiviral Res. 2024 Dec 27:106063. doi: 10.1016/j.antiviral.2024.106063.
    >> Share

  47. SHANNON A, Canard B
    Nucleotide analogues and mpox: Repurposing the repurposable.
    Antiviral Res. 2024;234:106057.
    >> Share

  48. WANG B, Xia H, Peng BH, Choi EJ, et al
    Pellino-1, a therapeutic target for control of SARS-CoV-2 infection and disease severity.
    Antiviral Res. 2024;233:106059.
    >> Share

  49. SCHRELL L, Fuchs HL, Dickmanns A, Scheibner D, et al
    Inhibitors of dihydroorotate dehydrogenase synergize with the broad antiviral activity of 4'-fluorouridine.
    Antiviral Res. 2024 Dec 3:106046. doi: 10.1016/j.antiviral.2024.106046.
    >> Share

  50. WELCH SR, Bilello JP, Carter K, Delang L, et al
    Meeting report of the 37th International Conference on Antiviral Research in Gold Coast, Australia, May 20-24, 2024, organized by the International Society for Antiviral Research.
    Antiviral Res. 2024;232:106037.
    >> Share

    November 2024
  51. AMIN MR, Anwar KN, Ashraf MJ, Ghassemi M, et al
    Preventing human influenza and coronaviral mono or coinfection by blocking virus-induced sialylation.
    Antiviral Res. 2024;232:106041.
    >> Share

  52. SRIWILAIJAROEN N, Hanamatsu H, Yokota I, Nishikaze T, et al
    Edible bird's nest: N- and O-glycan analysis and synergistic anti-avian influenza virus activity with neuraminidase inhibitors.
    Antiviral Res. 2024 Nov 20:106040. doi: 10.1016/j.antiviral.2024.106040.
    >> Share

  53. MCGOVERN-GOOCH KR, Mani N, Gotchev D, Ardzinski A, et al
    Biological characterization of AB-343, a novel and potent SARS-CoV-2 M(pro) inhibitor with pan-coronavirus activity.
    Antiviral Res. 2024;232:106038.
    >> Share

  54. SASAKI J, Sato A, Sasaki M, Okabe I, et al
    X-206 exhibits broad-spectrum anti-beta-coronavirus activity, covering SARS-CoV-2 variants and drug-resistant isolates.
    Antiviral Res. 2024 Nov 19:106039. doi: 10.1016/j.antiviral.2024.106039.
    >> Share

  55. ZHANG W, Lin X, Li ZY, Zhang LJ, et al
    Novel intercellular spread mode of respiratory syncytial virus contributes to neutralization escape.
    Antiviral Res. 2024;231:106023.
    >> Share

  56. ZHANG K, Yang XM, Sun H, Cheng ZS, et al
    Modulating apoptosis as a novel therapeutic strategy against Respiratory Syncytial Virus infection: insights from Rotenone.
    Antiviral Res. 2024;231:106007.
    >> Share

  57. RICHTER M, Khrenova M, Kazakova E, Riabova O, et al
    Dynamic features of virus protein 1 and substitutions in the 3-phenyl ring determine the potency and broad-spectrum activity of capsid-binding pyrazolo[3,4-d]pyrimidines against rhinoviruses.
    Antiviral Res. 2024;231:105993.
    >> Share

    October 2024
  58. NAKASHIMA M, Nobori H, Kuroda T, Shimba A, et al
    Oral 3CL protease inhibitor ensitrelvir suppressed SARS-CoV-2 shedding and infection in a hamster aerosol transmission model.
    Antiviral Res. 2024 Oct 28:106026. doi: 10.1016/j.antiviral.2024.106026.
    >> Share

  59. LO CW, Kariv O, Hao C, Gammeltoft KA, et al
    Replication Capacity and Susceptibility of Nirmatrelvir-Resistant Mutants to Next-Generation Mpro Inhibitors in a SARS-CoV-2 Replicon System.
    Antiviral Res. 2024 Oct 16:106022. doi: 10.1016/j.antiviral.2024.106022.
    >> Share

    September 2024
  60. VAN DER HORST D, Carter-Timofte ME, Danneels A, Silva da Costa L, et al
    Large-scale deep learning identifies the antiviral potential of PKI-179 and MTI-31 against coronaviruses.
    Antiviral Res. 2024;231:106012.
    >> Share

  61. HERRMANN A, Gege C, Wangen C, Wagner S, et al
    Orally Bioavailable RORgamma/DHODH Dual Host-Targeting Small Molecules with Broad-Spectrum Antiviral Activity.
    Antiviral Res. 2024 Sep 19:106008. doi: 10.1016/j.antiviral.2024.106008.
    >> Share

  62. KUMAR P, Zhang X, Shaha R, Kschischo M, et al
    Identification of antibody-resistant SARS-CoV-2 mutants via N4-Hydroxycytidine mutagenesis.
    Antiviral Res. 2024;231:106006.
    >> Share

  63. DO TND, Abdelnabi R, Boda B, Constant S, et al
    The triple combination of Remdesivir (GS-441524), Molnupiravir and Ribavirin is highly efficient in inhibiting coronavirus replication in human nasal airway epithelial cell cultures and in a hamster infection model.
    Antiviral Res. 2024 Sep 3:105994. doi: 10.1016/j.antiviral.2024.105994.
    >> Share

  64. BONNEUX B, Jacoby E, Ceconi M, Stobbelaar K, et al
    Direct-acting antivirals for RSV treatment, a review.
    Antiviral Res. 2024;229:105948.
    >> Share

    August 2024
  65. YAMASAKI M, Saso W, Yamamoto T, Sato M, et al
    Anti-SARS-CoV-2 gapmer antisense oligonucleotides targeting the main protease region of viral RNA.
    Antiviral Res. 2024;230:105992.
    >> Share

  66. LEE P, Kim J, Oh H, Kim CU, et al
    Coronavirus Nucleocapsid-based Vaccine Provides Partial Protection against Hetero-species Coronavirus in Murine Models.
    Antiviral Res. 2024 Aug 22:105991. doi: 10.1016/j.antiviral.2024.105991.
    >> Share

  67. CONG Y, Dixit S, Perry DL, Huzella LM, et al
    Characterization of therapeutic antibodies efficacy against multiple SARS-CoV-2 variants in the hamster model.
    Antiviral Res. 2024 Aug 13:105987. doi: 10.1016/j.antiviral.2024.105987.
    >> Share

  68. BONOMINI A, Zhang J, Ju H, Zago A, et al
    Synergistic activity of an RNA polymerase PA-PB1 interaction inhibitor with oseltamivir against human and avian influenza viruses in cell culture and in ovo.
    Antiviral Res. 2024 Aug 6:105980. doi: 10.1016/j.antiviral.2024.105980.
    >> Share

  69. HAN Z, Mai Q, Zhao Y, Liu X, et al
    Mosaic neuraminidase-based vaccine induces antigen-specific T cell responses against homologous and heterologous influenza viruses.
    Antiviral Res. 2024 Aug 6:105978. doi: 10.1016/j.antiviral.2024.105978.
    >> Share

  70. KEISER PT, Zhang W, Ricca M, Wacquiez A, et al
    Amidino-Rocaglates (ADRs), a class of synthetic rocaglates, are potent inhibitors of SARS-CoV-2 replication through inhibition of viral protein synthesis.
    Antiviral Res. 2024 Aug 6:105976. doi: 10.1016/j.antiviral.2024.105976.
    >> Share

  71. YOON KW, Chu KB, Eom GD, Mao J, et al
    Orally Dissolving Film as a Potential Vaccine Delivery Carrier to Prevent Influenza Virus Infection.
    Antiviral Res. 2024 Aug 5:105979. doi: 10.1016/j.antiviral.2024.105979.
    >> Share

    July 2024
  72. ROSALES R, McGovern BL, Rodriguez ML, Leiva-Rebollo R, et al
    Nirmatrelvir and Molnupiravir maintain potent in vitro and in vivo antiviral activity against circulating SARS-CoV-2 Omicron subvariants.
    Antiviral Res. 2024 Jul 25:105970. doi: 10.1016/j.antiviral.2024.105970.
    >> Share

  73. OLIVEIRA EH, Monteleone-Cassiano AC, Tavares L, Santos JC, et al
    A mimetic peptide of ACE2 protects against SARS-CoV-2 infection and decreases pulmonary inflammation related to COVID-19.
    Antiviral Res. 2024;229:105968.
    >> Share

  74. CHEN D, Su W, Choy KT, Chu YS, et al
    High throughput profiling identified PA-L106R amino acid substitution in A(H1N1)pdm09 influenza virus that confers reduced susceptibility to baloxavir in vitro.
    Antiviral Res. 2024 Jul 11:105961. doi: 10.1016/j.antiviral.2024.105961.
    >> Share

  75. ANDREEV K, Jones JC, Seiler P, Kandeil A, et al
    Genotypic and phenotypic susceptibility of emerging avian influenza A viruses to neuraminidase and cap-dependent endonuclease inhibitors.
    Antiviral Res. 2024 Jul 8:105959. doi: 10.1016/j.antiviral.2024.105959.
    >> Share

  76. XU Y, Sun F, Chuai Z, Wang J, et al
    Cold-adapted influenza vaccine carrying three repeats of a respiratory syncytial virus (RSV) fusion glycoprotein epitope site protects BALB/c mice and cotton rats against RSV infection.
    Antiviral Res. 2024 Jul 8:105960. doi: 10.1016/j.antiviral.2024.105960.
    >> Share

  77. YOTSUYANAGI H, Ohmagari N, Doi Y, Yamato M, et al
    Prevention of Post COVID-19 Condition by Early Treatment with Ensitrelvir in the Phase 3 SCORPIO-SR Trial.
    Antiviral Res. 2024 Jul 5:105958. doi: 10.1016/j.antiviral.2024.105958.
    >> Share

  78. CHON I, Wagatsuma K, Saito R, Tang JW, et al
    Detection of influenza A(H3N2) viruses with polymerase acidic subunit substitutions after and prior to baloxavir marboxil treatment during the 2022-2023 influenza season in Japan.
    Antiviral Res. 2024 Jul 3:105956. doi: 10.1016/j.antiviral.2024.105956.
    >> Share

  79. JI J, Tang T, Zhu M, Wu Z, et al
    Boosting the immune response in COVID-19 vaccines via an Alum:CpG complex adjuvant.
    Antiviral Res. 2024 Jul 2:105954. doi: 10.1016/j.antiviral.2024.105954.
    >> Share

  80. BONNEUX B, Shareef A, Tcherniuk S, Anson B, et al
    JNJ-7184, a respiratory syncytial virus inhibitor targeting the connector domain of the viral polymerase.
    Antiviral Res. 2024;227:105907.
    >> Share

    June 2024
  81. WILLIAMS N, Silva F, Schmolke M
    Harnessing host enhancers of SARS-CoV-2 entry as novel targets for antiviral therapy.
    Antiviral Res. 2024 Jun 28:105951. doi: 10.1016/j.antiviral.2024.105951.
    >> Share

  82. LV L, Yang X, Zhang Y, Ren X, et al
    hnRNPAB inhibits Influenza A virus infection by disturbing polymerase activity.
    Antiviral Res. 2024;228:105925.
    >> Share

  83. DANIELS A, Padariya M, Fletcher S, Ball K, et al
    Molecules targeting a novel homotrimer cavity of Spike protein attenuate replication of SARS-CoV-2.
    Antiviral Res. 2024;228:105949.
    >> Share

  84. BALIGA-GIL A, Soszynska-Jozwiak M, Ruszkowska A, Szczesniak I, et al
    Targeting sgRNA N secondary structure as a way of inhibiting SARS-CoV-2 replication.
    Antiviral Res. 2024 Jun 24:105946. doi: 10.1016/j.antiviral.2024.105946.
    >> Share

  85. LIU X, Zheng M, Zhang H, Feng B, et al
    Characterization and noncovalent inhibition of the K63-deubiquitinase activity of SARS-CoV-2 PLpro.
    Antiviral Res. 2024 Jun 22:105944. doi: 10.1016/j.antiviral.2024.105944.
    >> Share

  86. DICKEY TH, Salinas ND, Patel P, Orr-Gonzalez S, et al
    RBD design increases the functional antibody titers elicited by SARS-CoV-2 spike vaccination.
    Antiviral Res. 2024 Jun 18:105937. doi: 10.1016/j.antiviral.2024.105937.
    >> Share

  87. SUN Y, Wagatsuma K, Saito R, Sato I, et al
    Duration of fever in children infected with influenza A(H1N1)pdm09, A(H3N2) or B virus and treated with baloxavir marboxil, oseltamivir, laninamivir, or zanamivir in Japan during the 2012-2013 and 2019-2020 influenza seasons.
    Antiviral Res. 2024 Jun 17:105938. doi: 10.1016/j.antiviral.2024.105938.
    >> Share

  88. ZHAI G, Fu W, Yuan S, Sun P, et al
    A fusion protein approach to integrate antiviral and anti-inflammatory activities for developing new therapeutics against influenza A virus infection.
    Antiviral Res. 2024 Jun 9:105924. doi: 10.1016/j.antiviral.2024.105924.
    >> Share

  89. LI J, Cui H, Yao Y, Niu J, et al
    Anti-influenza activity of CPAVM1 protease secreted by Bacillus subtilis LjM2.
    Antiviral Res. 2024 Jun 6:105919. doi: 10.1016/j.antiviral.2024.105919.
    >> Share

  90. GUO M, Peng J, Guo P, Wang Q, et al
    Inhalation of 2, 4-di-tert-butylphenol-Loaded micelles suppresses respiratory syncytial virus infection in mice.
    Antiviral Res. 2024;226:105880.
    >> Share

    May 2024
  91. VAN LOY B, Stevaert A, Naesens L
    The coronavirus nsp15 endoribonuclease: a puzzling protein and pertinent antiviral drug target.
    Antiviral Res. 2024 May 31:105921. doi: 10.1016/j.antiviral.2024.105921.
    >> Share

  92. LE UNP, Chang YJ, Lu CH, Chen Y, et al
    Glycyrrhizic acid conjugates with amino acid methyl esters target the main protease, exhibiting antiviral activity against wild-type and nirmatrelvir-resistant SARS-CoV-2 variants.
    Antiviral Res. 2024;227:105920.
    >> Share

  93. FRANCO-MAY DA, Gomez-Carballo J, Barrera-Badillo G, Cruz-Ortiz MN, et al
    Low antiviral resistance in Influenza A and B viruses isolated in Mexico from 2010 to 2023.
    Antiviral Res. 2024;227:105918.
    >> Share

  94. LIANG Y, Xiao W, Peng Y, Zhang S, et al
    Development of Nanoparticle Vaccines Utilizing Designed Fc-Binding Homo-oligomers and RBD-Fc of SARS-CoV-2.
    Antiviral Res. 2024 May 21:105917. doi: 10.1016/j.antiviral.2024.105917.
    >> Share

  95. HUANG J, Wang W, Li H, Bai Y, et al
    Three in one: An effective and universal vaccine expressing heterologous tandem RBD trimer by rabies virus vector protects mice against SARS-CoV-2.
    Antiviral Res. 2024;227:105905.
    >> Share

  96. PANDEY K, Acharya A, Pal D, Jain P, et al
    SRX3177, a CDK4/6-PI3K-BET inhibitor, in combination with an RdRp inhibitor, Molnupiravir, or an entry inhibitor MU-UNMC-2, has potent antiviral activity against the Omicron variant of SARS-CoV-2.
    Antiviral Res. 2024;227:105904.
    >> Share

  97. SALGADO-BENVINDO C, Tas A, Zevenhoven-Dobbe JC, van der Meer Y, et al
    Characterization of SARS-CoV-2 replication in human H1299/ACE2 cells: a versatile and practical infection model for antiviral research and beyond.
    Antiviral Res. 2024 May 7:105903. doi: 10.1016/j.antiviral.2024.105903.
    >> Share

    April 2024
  98. LIU X, Wang Y, Sun L, Xiao G, et al
    Screening and optimization of shark nanobodies against SARS-CoV-2 Spike RBD.
    Antiviral Res. 2024 Apr 29:105898. doi: 10.1016/j.antiviral.2024.105898.
    >> Share

  99. ARDUINO I, Francese R, Civra A, Feyles E, et al
    Polyoxometalate exerts broad-spectrum activity against human respiratory viruses hampering viral entry.
    Antiviral Res. 2024;226:105897.
    >> Share

  100. AMERATUNGA R, Jordan A, Lehnert K, Leung E, et al
    SARS-CoV-2 evolution has increased resistance to monoclonal antibodies and first-generation COVID-19 vaccines: Is there a future therapeutic role for soluble ACE2 receptors for COVID-19?
    Antiviral Res. 2024 Apr 25:105894. doi: 10.1016/j.antiviral.2024.105894.
    >> Share

  101. GLITSCHER M, Benz NI, Sabino C, Murra RO, et al
    Inhibition of Pim kinases triggers a broad antiviral activity by affecting innate immunity and via the PI3K-Akt-mTOR axis the endolysosomal system.
    Antiviral Res. 2024;226:105891.
    >> Share

  102. TOLKSDORF B, Heinze J, Niemeyer D, Rohrs V, et al
    Development of a highly stable, active small interfering RNA with broad activity against SARS-CoV viruses.
    Antiviral Res. 2024 Apr 8:105879. doi: 10.1016/j.antiviral.2024.105879.
    >> Share

    March 2024
  103. RAHA JR, Kim KH, Bhatnagar N, Liu R, et al
    Supplementation of seasonal vaccine with multi-subtype neuraminidase and M2 ectodomain virus-like particle improves protection against homologous and heterologous influenza viruses in aged mice.
    Antiviral Res. 2024;225:105877.
    >> Share

  104. KHATUA K, Alugubelli YR, Yang KS, Vulupala VR, et al
    Azapeptides with unique covalent warheads as SARS-CoV-2 main protease inhibitors.
    Antiviral Res. 2024;225:105874.
    >> Share

  105. SINIAVIN AE, Gushchin VA, Shastina NS, Darnotuk ES, et al
    New conjugates based on N4-hydroxycytidine with more potent antiviral efficacy in vitro than EIDD-2801 against SARS-CoV-2 and other human coronaviruses.
    Antiviral Res. 2024 Mar 28:105871. doi: 10.1016/j.antiviral.2024.105871.
    >> Share

  106. PEREZ-VARGAS J, Lemieux G, Thompson CAH, Desilets A, et al
    Nanomolar anti-SARS-CoV-2 Omicron activity of the host-directed TMPRSS2 inhibitor N-0385 and synergistic action with direct-acting antivirals.
    Antiviral Res. 2024 Mar 26:105869. doi: 10.1016/j.antiviral.2024.105869.
    >> Share

  107. MOON C, Porges E, Roberts A, Bacon J, et al
    A combination of nirmatrelvir and ombitasvir boosts inhibition of SARS-CoV-2 replication.
    Antiviral Res. 2024 Mar 14:105859. doi: 10.1016/j.antiviral.2024.105859.
    >> Share

  108. BANDYSZEWSKA M, Ambrozek-Latecka M, Hoser G, Grzanka M, et al
    SARS-CoV-2 virus-like particle variants alpha and delta mimic the native viruses in their differential inflammasome activating potential.
    Antiviral Res. 2024 Mar 5:105857. doi: 10.1016/j.antiviral.2024.105857.
    >> Share

  109. WANG W, Wang S, Meng X, Zhao Y, et al
    A virus-like particle candidate vaccine based on CRISPR/Cas9 gene editing technology elicits broad-spectrum protection against SARS-CoV-2.
    Antiviral Res. 2024 Mar 4:105854. doi: 10.1016/j.antiviral.2024.105854.
    >> Share

  110. KLEVANSKI M, Kim H, Heilemann M, Kuner T, et al
    Glycan-directed SARS-CoV-2 inhibition by leek extract and lectins with insights into the mode-of-action of Concanavalin A.
    Antiviral Res. 2024 Mar 4:105856. doi: 10.1016/j.antiviral.2024.105856.
    >> Share

  111. SCHREIBER A, Rodner F, Oberberg N, Anhlan D, et al
    The host-targeted antiviral drug Zapnometinib exhibits a high barrier to the development of SARS-CoV-2 resistance.
    Antiviral Res. 2024 Mar 2:105840. doi: 10.1016/j.antiviral.2024.105840.
    >> Share

    February 2024
  112. GOTO T, Kawai N, Bando T, Takasaki Y, et al
    Virological and clinical outcomes in outpatients treated with baloxavir or neuraminidase inhibitors for A(H3N2) influenza: A multicenter study of the 2022-2023 season.
    Antiviral Res. 2024;224:105853.
    >> Share

  113. NOBORI H, Baba K, Kuroda T, Baba K, et al
    Prophylactic effect of ensitrelvir in mice infected with SARS-CoV-2.
    Antiviral Res. 2024;224:105852.
    >> Share

  114. LI H, Sun M, Lei F, Liu J, et al
    Methyl rosmarinate is an allosteric inhibitor of SARS-cov-2 3?C?L protease as a potential candidate against SARS-cov-2 infection.
    Antiviral Res. 2024 Feb 24:105841. doi: 10.1016/j.antiviral.2024.105841.
    >> Share

  115. BIGOTTI MG, Klein K, Gan ES, Anastasina M, et al
    The alpha-dystroglycan N-terminus is a broad-spectrum antiviral agent against SARS-CoV-2 and enveloped viruses.
    Antiviral Res. 2024 Feb 20:105837. doi: 10.1016/j.antiviral.2024.105837.
    >> Share

  116. ZHANG X, Xia Y, Li P, Wu Z, et al
    Discovery of cyperenoic acid as a potent and novel entry inhibitor of influenza A virus.
    Antiviral Res. 2024 Feb 11:105822. doi: 10.1016/j.antiviral.2024.105822.
    >> Share

  117. SINHA D, Yaugel-Novoa M, Waeckel L, Paul S, et al
    Unmasking the potential of secretory IgA and its pivotal role in protection from respiratory viruses.
    Antiviral Res. 2024 Feb 6:105823. doi: 10.1016/j.antiviral.2024.105823.
    >> Share

  118. IZMAILYAN R, Matevosyan M, Khachatryan H, Shavina A, et al
    Discovery of new antiviral agents through artificial intelligence: In vitro and in vivo results.
    Antiviral Res. 2024;222:105818.
    >> Share

  119. RICHTER M, Doring K, Blaas D, Riabova O, et al
    Molecular mechanism of rhinovirus escape from the Pyrazolo[3,4-d]pyrimidine capsid-binding inhibitor OBR-5-340 via mutations distant from the binding pocket: Derivatives that brake resistance.
    Antiviral Res. 2024;222:105810.
    >> Share

  120. LOAIZA RA, Ramirez RA, Sepulveda-Alfaro J, Ramirez MA, et al
    A molecular perspective for the development of antibodies against the human respiratory syncytial virus.
    Antiviral Res. 2024;222:105783.
    >> Share

    January 2024
  121. WINIGER RR, Perez L
    Therapeutic antibodies and alternative formats against SARS-CoV-2.
    Antiviral Res. 2024 Jan 31:105820. doi: 10.1016/j.antiviral.2024.105820.
    >> Share

  122. BOUZIDI HS, Driouich JS, Klitting R, Bernadin O, et al
    Generation and evaluation of protease inhibitor-resistant SARS-CoV-2 strains.
    Antiviral Res. 2024 Jan 23:105814. doi: 10.1016/j.antiviral.2024.105814.
    >> Share

  123. BOGACHEVA MS, Kuivanen S, Potdar S, Hassinen A, et al
    Drug repurposing platform for deciphering the druggable SARS-CoV-2 interactome.
    Antiviral Res. 2024 Jan 23:105813. doi: 10.1016/j.antiviral.2024.105813.
    >> Share

  124. IDRIS A, Supramaniam A, Tayyar Y, Kelly G, et al
    An intranasally delivered ultra-conserved siRNA prophylactically represses SARS-CoV-2 infection in the lung and nasal cavity.
    Antiviral Res. 2024;222:105815.
    >> Share

  125. MATTHYS A, Saelens X
    Promises and challenges of single-domain antibodies to control influenza.
    Antiviral Res. 2024 Jan 12:105807. doi: 10.1016/j.antiviral.2024.105807.
    >> Share

  126. GOVEDNIK T, Lainscek D, Kuhar U, Lachish M, et al
    TXM peptides inhibit SARS-CoV-2 infection, syncytia formation, and lower inflammatory consequences.
    Antiviral Res. 2024 Jan 9:105806. doi: 10.1016/j.antiviral.2024.105806.
    >> Share

  127. ZOU G, Cao S, Gao Z, Yie J, et al
    Current state and challenges in respiratory syncytial virus drug discovery and development.
    Antiviral Res. 2024;221:105791.
    >> Share

    December 2023
  128. CHEN X, Tian L, Zhang L, Gao W, et al
    Deubiquitinase USP39 promotes SARS-CoV-2 replication by deubiquitinating and stabilizing the envelope protein.
    Antiviral Res. 2023;221:105790.
    >> Share

  129. SUN X, Ma H, Wang X, Bao Z, et al
    Broadly neutralizing antibodies to combat influenza virus infection.
    Antiviral Res. 2023 Dec 23:105785. doi: 10.1016/j.antiviral.2023.105785.
    >> Share

  130. AKSU M, Kumar P, Guttler T, Taxer W, et al
    Nanobodies to multiple spike variants and inhalation of nanobody-containing aerosols neutralize SARS-CoV-2 in cell culture and hamsters.
    Antiviral Res. 2023 Dec 6:105778. doi: 10.1016/j.antiviral.2023.105778.
    >> Share

  131. ZUR M, Peselev T, Yanko S, Rotshild V, et al
    Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: Systematic review and network meta-analysis.
    Antiviral Res. 2023 Dec 4:105768. doi: 10.1016/j.antiviral.2023.105768.
    >> Share

    November 2023
  132. WANG S, Cui H, Zhang C, Li W, et al
    Oral delivery of a chitosan adjuvanted COVID-19 vaccine provides long-lasting and broad-spectrum protection against SARS-CoV-2 variants of concern in golden hamsters.
    Antiviral Res. 2023 Nov 28:105765. doi: 10.1016/j.antiviral.2023.105765.
    >> Share

  133. GOMEZ-CARBALLA A, Albericio G, Montoto-Louzao J, Perez P, et al
    Lung transcriptomics of K18-hACE2 mice highlights mechanisms and genes involved in the MVA-S vaccine-mediated immune response and protection against SARS-CoV-2 infection.
    Antiviral Res. 2023 Nov 20:105760. doi: 10.1016/j.antiviral.2023.105760.
    >> Share

  134. WU CY, Tseng YC, Kao SE, Wu LY, et al
    Monoglycosylated SARS-CoV-2 receptor binding domain fused with HA(stem)-scaffolded protein vaccine confers broad protective immunity against SARS-CoV-2 and influenza viruses.
    Antiviral Res. 2023 Nov 18:105759. doi: 10.1016/j.antiviral.2023.105759.
    >> Share

  135. ZHANG QY, Zhang HQ, Zhang YN, Zhang ZR, et al
    Newcastle Disease Virus (NDV)-based vaccine candidate against SARS-CoV-2 Omicron by intranasal immunization.
    Antiviral Res. 2023 Nov 18:105757. doi: 10.1016/j.antiviral.2023.105757.
    >> Share

  136. SADHU S, Dandotiya J, Dalal R, Khatri R, et al
    Fangchinoline inhibits SARS-CoV-2 and MERS-CoV entry.
    Antiviral Res. 2023 Nov 8:105743. doi: 10.1016/j.antiviral.2023.105743.
    >> Share

  137. HSIEH HC, Chen CC, Chou PH, Liu WC, et al
    Induction of neutralizing antibodies and mucosal IgA through intranasal immunization with the receptor binding domain of SARS-CoV-2 spike protein fused with the type IIb E. coli heat-labile enterotoxin A subunit.
    Antiviral Res. 2023 Nov 8:105752. doi: 10.1016/j.antiviral.2023.105752.
    >> Share

  138. SU WC, Chen ZY, Chang YS, Jeng KS, et al
    Functional assessments of SARS-CoV-2 single-round infectious particles with variant-specific spike proteins on infectivity, drug sensitivity, and antibody neutralization.
    Antiviral Res. 2023 Nov 7:105744. doi: 10.1016/j.antiviral.2023.105744.
    >> Share

  139. KIM DG, Kim U, Park IH, Ryu B, et al
    A bivalent form of a RBD-specific synthetic antibody effectively neutralizes SARS-CoV-2 variants.
    Antiviral Res. 2023 Nov 7:105738. doi: 10.1016/j.antiviral.2023.105738.
    >> Share

  140. LUGANINI A, Sibille G, Pavan M, Mello Grand M, et al
    Mechanisms of antiviral activity of the new hDHODH inhibitor MEDS433 against respiratory syncytial virus replication.
    Antiviral Res. 2023;219:105734.
    >> Share

    October 2023
  141. DEMIAN WL, Jacob RA, Cormier O, Nazli A, et al
    ASK1 inhibitors are potential pan-antiviral drugs, which dampen replication of diverse viruses including SARS-CoV2.
    Antiviral Res. 2023 Oct 18:105736. doi: 10.1016/j.antiviral.2023.105736.
    >> Share

  142. PALLA SR, Li CW, Chao TL, Lo HV, et al
    Synthesis, evaluation, and mechanism of 1-(4-(arylethylenylcarbonyl)phenyl)-4-carboxy-2-pyrrolidinones as potent reversible SARS-CoV-2 entry inhibitors.
    Antiviral Res. 2023 Oct 17:105735. doi: 10.1016/j.antiviral.2023.105735.
    >> Share

  143. KONKEL R, Milewska A, Do NDT, Barreto Duran E, et al
    Anti-SARS-CoV-2 activity of cyanopeptolins produced by Nostoc edaphicum CCNP1411.
    Antiviral Res. 2023 Oct 12:105731. doi: 10.1016/j.antiviral.2023.105731.
    >> Share

    September 2023
  144. GAO R, Pascua PNQ, Nguyen HT, Chesnokov A, et al
    New insights into the neuraminidase-mediated hemagglutination activity of influenza A(H3N2) viruses.
    Antiviral Res. 2023;218:105719.
    >> Share

  145. BENNETT RP, Yoluc Y, Salter JD, Ripp A, et al
    Sangivamycin is preferentially incorporated into viral RNA by the SARS-CoV-2 polymerase.
    Antiviral Res. 2023 Sep 8:105716. doi: 10.1016/j.antiviral.2023.105716.
    >> Share

    August 2023
  146. IVASHCHENKO AA, Jones JC, Shkil DO, Ivanenkov YA, et al
    Resistance profiles for the investigational neuraminidase inhibitor AV5080 in influenza A and B viruses.
    Antiviral Res. 2023;217:105701.
    >> Share

  147. VANDERLINDEN E, Boonen A, Noppen S, Schoofs G, et al
    PRO-2000 exhibits SARS-CoV-2 antiviral activity by interfering with spike-heparin binding.
    Antiviral Res. 2023;217:105700.
    >> Share

  148. CORONA A, Madia VN, De Santis R, Manelfi C, et al
    Diketo acid inhibitors of nsp13 of SARS-CoV-2 block viral replication.
    Antiviral Res. 2023;217:105697.
    >> Share

    July 2023
  149. NGUYEN HT, Chesnokov A, De La Cruz J, Pascua PNQ, et al
    Antiviral susceptibility of clade 2.3.4.4b highly pathogenic avian influenza A(H5N1) viruses isolated from birds and mammals in the United States, 2022.
    Antiviral Res. 2023 Jul 24:105679. doi: 10.1016/j.antiviral.2023.105679.
    >> Share

  150. SPENGLER JR, Carter K, Delang L, Durantel D, et al
    Meeting report: 36th international conference on antiviral research in Lyon, France, March 13-17, 2023.
    Antiviral Res. 2023 Jul 24:105678. doi: 10.1016/j.antiviral.2023.105678.
    >> Share

  151. SUPREWICZ L, Szczepanski A, Lenart M, Piktel E, et al
    Ceragenins exhibit antiviral activity against SARS-CoV-2 by increasing the expression and release of type I interferons upon activation of the host's immune response.
    Antiviral Res. 2023 Jul 20:105676. doi: 10.1016/j.antiviral.2023.105676.
    >> Share

  152. BOWDEN-REID E, Ledger S, Zhang Y, Di Giallonardo F, et al
    Novel siRNA therapeutics demonstrate multi-variant efficacy against SARS-CoV-2.
    Antiviral Res. 2023 Jul 19:105677. doi: 10.1016/j.antiviral.2023.105677.
    >> Share

  153. TAKASHITA E, Fujisaki S, Morita H, Nagata S, et al
    Assessment of the frequency of SARS-CoV-2 Omicron variant escape from RNA-dependent RNA polymerase inhibitors and 3C-like protease inhibitors.
    Antiviral Res. 2023;216:105671.
    >> Share

  154. JEONG JH, Choi JH, Kim BK, Min SC, et al
    Evaluating Z-FA-FMK, a host cathepsin L protease inhibitor, as a potent and broad-spectrum antiviral therapy against SARS-CoV-2 and related coronaviruses.
    Antiviral Res. 2023 Jul 10:105669. doi: 10.1016/j.antiviral.2023.105669.
    >> Share

  155. FENG Y, Yang Y, Zou S, Qiu S, et al
    Identification of alpha-linolenic acid as a broad-spectrum antiviral against zika, dengue, herpes simplex, influenza virus and SARS-CoV-2 infection.
    Antiviral Res. 2023 Jul 8:105666. doi: 10.1016/j.antiviral.2023.105666.
    >> Share

    June 2023
  156. MU S, Zou X, Wang Y, Deng X, et al
    The combined effect of oseltamivir and favipiravir on influenza a virus evolution in patients hospitalized with severe influenza.
    Antiviral Res. 2023 Jun 25:105657. doi: 10.1016/j.antiviral.2023.105657.
    >> Share

  157. CAI H, Yan J, Liu S, Li P, et al
    Paxlovid for hospitalized COVID-19 patients with chronic kidney disease.
    Antiviral Res. 2023 Jun 25:105659. doi: 10.1016/j.antiviral.2023.105659.
    >> Share

  158. MILAN BONOTTO R, Mitrovic A, Sosic I, Martinez-Orellana P, et al
    Cathepsin inhibitors nitroxoline and its derivatives inhibit SARS-CoV-2 infection.
    Antiviral Res. 2023;216:105655.
    >> Share

  159. JUNG HE, Ku KB, Kang BH, Park JH, et al
    Intranasal delivery of an adenovirus-vector vaccine co-expressing a modified spike protein and a genetic adjuvant confers lasting mucosal immunity against SARS-CoV-2.
    Antiviral Res. 2023;216:105656.
    >> Share

  160. CHANG YJ, Le UNP, Liu JJ, Li SR, et al
    Combining virtual screening with cis-/trans-cleavage enzymatic assays effectively reveals broad-spectrum inhibitors that target the main proteases of SARS-CoV-2 and MERS-CoV.
    Antiviral Res. 2023 Jun 13:105653. doi: 10.1016/j.antiviral.2023.105653.
    >> Share

  161. ZHANG J, Nian X, Liu B, Zhang Z, et al
    Development of MDCK-based quadrivalent split seasonal influenza virus vaccine with high safety and immunoprotection: A preclinical study.
    Antiviral Res. 2023;216:105639.
    >> Share

    May 2023
  162. WU CY, Kao SE, Tseng YC, Lin YP, et al
    Pilot-scale production of inactivated monoglycosylated split H(1)N(1) influenza virus vaccine provides cross-strain protection against influenza viruses.
    Antiviral Res. 2023 May 30:105640. doi: 10.1016/j.antiviral.2023.105640.
    >> Share

  163. WANG X, Lin L, Chen Z, Si W, et al
    Mutations at site 207 of influenza a virus NS1 protein switch its function in regulating RIG-I-like receptors mediated antiviral responses.
    Antiviral Res. 2023 May 23:105641. doi: 10.1016/j.antiviral.2023.105641.
    >> Share

  164. DRIOUICH JS, Bernadin O, Touret F, de Lamballerie X, et al
    Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster model.
    Antiviral Res. 2023 May 17:105638. doi: 10.1016/j.antiviral.2023.105638.
    >> Share

  165. HUANG X, Fan W, Sun J, Yang J, et al
    SARS-CoV-2 induces cardiomyocyte apoptosis and inflammation but can be ameliorated by ACE inhibitor Captopril.
    Antiviral Res. 2023 May 17:105636. doi: 10.1016/j.antiviral.2023.105636.
    >> Share

  166. HU J, Zhang L, Zheng X, Wang G, et al
    Long noncoding RNA #61 exerts a broad anti-influenza a virus effect by its long arm rings.
    Antiviral Res. 2023 May 15:105637. doi: 10.1016/j.antiviral.2023.105637.
    >> Share

  167. YANG X, Long F, Jia W, Zhang M, et al
    Artesunate inhibits PDE4 leading to intracellular cAMP accumulation, reduced ERK/MAPK signaling, and blockade of influenza A virus vRNP nuclear export.
    Antiviral Res. 2023 May 14:105635. doi: 10.1016/j.antiviral.2023.105635.
    >> Share

    April 2023
  168. CHO J, Shin Y, Yang JS, Kim JW, et al
    Evaluation of antiviral drugs against newly emerged SARS-CoV-2 Omicron subvariants.
    Antiviral Res. 2023;214:105609.
    >> Share

  169. LI Y, Wang K, Sun H, Wu S, et al
    Omicsynin B4 potently blocks coronavirus infection by inhibiting host proteases cathepsin L and TMPRSS2.
    Antiviral Res. 2023 Apr 17:105606. doi: 10.1016/j.antiviral.2023.105606.
    >> Share

  170. CONG Y, Lee JH, Perry DL, Cooper K, et al
    Longitudinal analyses using (18)F-Fluorodeoxyglucose positron emission tomography with computed tomography as a measure of COVID-19 severity in the aged, young, and humanized ACE2 SARS-CoV-2 hamster models.
    Antiviral Res. 2023 Apr 15:105605. doi: 10.1016/j.antiviral.2023.105605.
    >> Share

    March 2023
  171. SON S, Ahn SB, Kim G, Jang Y, et al
    Identification of broad-spectrum neutralizing antibodies against influenza A virus and evaluation of their prophylactic efficacy in mice.
    Antiviral Res. 2023;213:105591.
    >> Share

  172. BILLS C, Xie X, Shi PY
    The multiple roles of nsp6 in the molecular pathogenesis of SARS-CoV-2.
    Antiviral Res. 2023;213:105590.
    >> Share

  173. CONG Y, Mucker EM, Perry DL, Dixit S, et al
    Evaluation of a panel of therapeutic antibody clinical candidates for efficacy against SARS-CoV-2 in Syrian hamsters.
    Antiviral Res. 2023;213:105589.
    >> Share

  174. YANG Y, Cao L, Yan M, Zhou J, et al
    Synthesis of deuterated S-217622 (Ensitrelvir) with antiviral activity against coronaviruses including SARS-CoV-2.
    Antiviral Res. 2023 Mar 28:105586. doi: 10.1016/j.antiviral.2023.105586.
    >> Share

  175. VANHULLE E, Doijen J, Stroobants J, Provinciael B, et al
    Cellular electrical impedance to profile SARS-CoV-2 fusion inhibitors and to assess the fusogenic potential of spike mutants.
    Antiviral Res. 2023;213:105587.
    >> Share

  176. DICHTL S, Diem G, Jager M, Zaderer V, et al
    Antiviral drugs block replication of highly immune-evasive Omicron subvariants ex vivo, but fail to reduce tissue inflammation.
    Antiviral Res. 2023 Mar 23:105581. doi: 10.1016/j.antiviral.2023.105581.
    >> Share

  177. ALVES RPDS, Wang YT, Mikulski Z, McArdle S, et al
    SARS-CoV-2 Omicron (B.1.1.529) shows minimal neurotropism in a double-humanized mouse model.
    Antiviral Res. 2023 Mar 18:105580. doi: 10.1016/j.antiviral.2023.105580.
    >> Share

  178. LU C, Zhang Y, Liu X, Hou F, et al
    Heterologous boost with mRNA vaccines against SARS-CoV-2 Delta/Omicron variants following an inactivated whole-virus vaccine.
    Antiviral Res. 2023;212:105556.
    >> Share

  179. KIM JW, Heo K, Kim HJ, Yoo Y, et al
    Novel bispecific human antibody platform specifically targeting a fully open spike conformation potently neutralizes multiple SARS-CoV-2 variants.
    Antiviral Res. 2023;212:105576.
    >> Share

  180. SHEKUNOV EV, Zlodeeva PD, Efimova SS, Muryleva AA, et al
    Cyclic lipopeptides as membrane fusion inhibitors against SARS-CoV-2: New tricks for old dogs.
    Antiviral Res. 2023;212:105575.
    >> Share

  181. ISSMAIL L, Ramsbeck D, Jager C, Henning T, et al
    Identification and evaluation of a novel tribenzamide derivative as an inhibitor targeting the entry of the respiratory syncytial virus.
    Antiviral Res. 2023;211:105547.
    >> Share

  182. HU Y, Zhu Y, Yu Y, Liu N, et al
    Design and characterization of novel SARS-CoV-2 fusion inhibitors with N-terminally extended HR2 peptides.
    Antiviral Res. 2023;212:105571.
    >> Share

    February 2023
  183. XIAO Y, Yan Y, Chang L, Ji H, et al
    CDK4/6 inhibitor palbociclib promotes SARS-CoV-2 cell entry by down-regulating SKP2 dependent ACE2 degradation.
    Antiviral Res. 2023 Feb 18:105558. doi: 10.1016/j.antiviral.2023.105558.
    >> Share

  184. LI J, Wang Y, Solanki K, Atre R, et al
    Nirmatrelvir exerts distinct antiviral potency against different human coronaviruses.
    Antiviral Res. 2023 Feb 13:105555. doi: 10.1016/j.antiviral.2023.105555.
    >> Share

  185. MERINO VF, Yan Y, Ordonez AA, Bullen CK, et al
    Nucleolin mediates SARS-CoV-2 replication and viral-induced apoptosis of host cells.
    Antiviral Res. 2023;211:105550.
    >> Share

    January 2023
  186. ZHU Y, Li M, Liu N, Wu T, et al
    Development of highly effective LCB1-based lipopeptides targeting the spike receptor-binding motif of SARS-CoV-2.
    Antiviral Res. 2023;211:105541.
    >> Share

  187. BASILE A, Zannella C, De Marco M, Sanna G, et al
    Spike-mediated viral membrane fusion is inhibited by a specific anti-IFITM2 monoclonal antibody.
    Antiviral Res. 2023;211:105546.
    >> Share

    December 2022
  188. SPENGLER JR, Welch SR, Deval J, Gentry BG, et al
    Meeting report: 35th international conference on antiviral research in Seattle, WA, USA - March 21-25, 2022.
    Antiviral Res. 2022 Dec 31:105521. doi: 10.1016/j.antiviral.2022.105521.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016